Uhl, L., Aziba, A., Lobbert, S., Russell, T., Krenz, B., Montesinos, F., Kannan, T., Valanju, O.R., Schulein-Volk, C., de Martines, T., Bolz, M., Fleischhauer, D., Cossa, G., Endres, T., Solvie, D., Gallant, P., Rosenwald, A., Maric, H.M., Papadopoulos, D., Vos, S.M., and Eilers, M. (2026). MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids. Cell, 189(5), 1371-1388 e1329. doi: 10.1016/j.cell.2025.12.019
Krenz B*, Lee J*, Kannan T, Eilers M (2024) Immune evasion: An imperative or consequence of MYC deregulation. Mol Onc, doi: 10.1002/1878-0261.13695
Papadopoulos D*, Ha S*, Fleischhauer D*, ..., Eilers M (2024) The MCYN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. Mol Cell, doi: 10.1016/j.molcel.2024.04.007
Gaballa A*, Gebhardt-Wolf A*, ..., Eilers M (2024) PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma. Nat Commun, doi: 10.1038/s41467-024-45760-8
Hofstetter J*, Ogunleye A*,..., Gallant P (2024) Spt5 interacts genetically with Myc and is limiting for brain tumor growth in Drosophila. Life Sci Alliance doi: 10.26508/lsa.202302130
Solvie D*, Baluapuri A*, Uhl L*, ..., Wolf E, Eilers M (2022) MYC multimers shield stalled replication forks from RNA polymerase. Nature doi: 10.1038/s41586-022-05469-4
Zimmerli D, Brambillasca CS, ..., Eilers M, ..., Jonkers J. (2022) MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun doi: 10.1038/s41467-022-34000-6.
Bozilovic J*, Eing L*, ..., Wolf E*, Knapp S* (2022) Novel, highly potent PROTACs targeting AURORA-A kinase. Cur Res Chem Bio doi: 10.1016/j.crchbi.2022.100032.
